James Jiao
Janssen (United States)(US)
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Prostate Cancer Treatment and Research, PI3K/AKT/mTOR signaling in cancer, Hormonal and reproductive studies
Most-Cited Works
- → Peginterferon alfa‐2a for hepatitis C after liver transplantation(2005)277 cited
- → Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer(2015)102 cited
- → Abiraterone Acetate to Lower Androgens in Women With Classic 21-Hydroxylase Deficiency(2014)91 cited
- → Stable isotope‐labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults(2015)70 cited
- → Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer(2020)51 cited
- → A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies(2018)47 cited
- → Impact on abiraterone pharmacokinetics and safety: Open‐label drug–drug interaction studies with ketoconazole and rifampicin(2014)32 cited
- → Single‐dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment(2013)31 cited
- → Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study(2017)28 cited
- → An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer(2018)26 cited